KDR and renal cell carcinoma: The first set primarily controls the pathways for tumor growth and angiogenesis by interfering with genes and proteins, such as vascular endothelial growth factor receptor (VEGFR) inhibitors and mammalian target of rapamycin (mTOR) inhibitors, which are commonly employed for advanced RCC, which is the most common subtype of KC33.